Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.

Uckun FM, Qazi S, Cely I, Sahin K, Shahidzadeh A, Ozercan I, Yin Q, Gaynon P, Termuhlen A, Cheng J, Yiv S.

Blood. 2013 May 23;121(21):4348-54. doi: 10.1182/blood-2012-11-470633. Epub 2013 Apr 8.

2.

Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.

Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S.

Br J Haematol. 2010 May;149(4):508-17. doi: 10.1111/j.1365-2141.2010.08106.x. Epub 2010 Feb 11.

PMID:
20151979
3.

CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.

Myers DE, Yiv S, Qazi S, Ma H, Cely I, Shahidzadeh A, Arellano M, Finestone E, Gaynon PS, Termuhlen A, Cheng J, Uckun FM.

Integr Biol (Camb). 2014 Aug;6(8):766-80. doi: 10.1039/c4ib00095a.

4.
5.

Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).

Uckun FM, Dibirdik I, Qazi S.

Radiat Res. 2010 Oct;174(4):526-31. doi: 10.1667/RR2246.1.

PMID:
20731589
6.
7.

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM.

J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7.

8.

Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.

Uckun FM, Myers DE, Qazi S, Ozer Z, Rose R, D'Cruz OJ, Ma H.

J Clin Invest. 2015 Mar 2;125(3):1006-18. doi: 10.1172/JCI76610. Epub 2015 Jan 26.

9.

Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.

Cely I, Yiv S, Yin Q, Shahidzadeh A, Tang L, Cheng J, Uckun FM.

J Anal Oncol. 2012 Jun 25;1(1):1-9.

10.

Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.

Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM.

Oncogene. 2001 Jul 5;20(30):3969-78.

11.

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.

Perova T, Grandal I, Nutter LM, Papp E, Matei IR, Beyene J, Kowalski PE, Hitzler JK, Minden MD, Guidos CJ, Danska JS.

Sci Transl Med. 2014 May 14;6(236):236ra62. doi: 10.1126/scitranslmed.3008661.

12.

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK.

Blood. 2009 Sep 24;114(13):2678-87. doi: 10.1182/blood-2009-03-209247. Epub 2009 Jul 30. Retraction in: Blood. 2012 Aug 16;120(7):1533.

13.

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.

Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C.

Br J Haematol. 2010 Mar;148(5):714-25. doi: 10.1111/j.1365-2141.2009.07983.x. Epub 2009 Nov 12.

PMID:
19912216
14.

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.

Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K.

Blood. 2010 Jun 3;115(22):4497-506. doi: 10.1182/blood-2009-07-233692. Epub 2010 Mar 24.

15.

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.

Uckun FM, Qazi S.

Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112. Review.

PMID:
20836676
16.

Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL.

Castro Alves C, Terziyska N, Grunert M, Gündisch S, Graubner U, Quintanilla-Martinez L, Jeremias I.

Blood. 2012 May 3;119(18):4224-7. doi: 10.1182/blood-2011-08-370114. Epub 2012 Mar 9.

17.

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.

Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, Hollenbach SJ, Phillips DR, Sinha U.

J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31.

18.

Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.

Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, Bondada S.

J Immunol. 2007 Jan 1;178(1):111-21.

19.
20.

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.

Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, Leone G, Efremov DG.

Leukemia. 2009 Apr;23(4):686-97. doi: 10.1038/leu.2008.346. Epub 2008 Dec 18.

PMID:
19092849
Items per page

Supplemental Content

Write to the Help Desk